EMILY GREENLEY: Open Payments
NPI 1497104814 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,160 in 74 payments from 19 companies in 2025. Trend: 2023 $1,458 · 2024 $1,400 · 2025 $1,160
Food & beverage: $1,160
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $301 |
| Lilly USA, LLC | 10 | $158 |
| Dexcom, Inc. | 13 | $139 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $97 |
| Eisai Inc. | 3 | $87 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Novartis Pharmaceuticals Corporation | 2 | $30 |
| GlaxoSmithKline, LLC. | 2 | $29 |
Products named: VRAYLAR, MOUNJARO, Dexcom G6 Transmitter, JARDIANCE, Leqembi, GEMTESA, UBRELVY, QULIPTA.
Industry payments across MO — which companies pay providers there.
